[CAS NO. 2061894-48-0] Belantamab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2061894-48-0]

Catalog

HY-P9980

Brand

MCE

CAS

2061894-48-0

DESCRIPTION [2061894-48-0]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Belantamab]

For research use only. We do not sell to patients.

Summary

Belantamab (GSK2857914) is a humanised IgG1 anti- BCMA (TNFRSF17) monoclonal antibody. Belantamab can be used in the synthesis of antibody-drug conjugate (ADC), Belantamab mafodotin ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05208307	Emory University\|GlaxoSmithKline\|National Cancer Institute (NCI)	Plasma Cell Myeloma	July 21, 2022	Phase 2
NCT03544281	GlaxoSmithKline\|Iqvia Pty Ltd	Multiple Myeloma	September 20, 2018	Phase 1\|Phase 2
NCT05461209	Janssen Research & Development, LLC	Relapsed+ Refractory Multiple Myeloma	October 20, 2022	Phase 3
NCT04876248	Roswell Park Cancer Institute\|GlaxoSmithKline	Plasma Cell Myeloma	December 1, 2022	Phase 2
NCT04892264	Mayo Clinic\|National Cancer Institute (NCI)	Plasma Cell Myeloma\|Recurrent Plasma Cell Myeloma\|Refractory Plasma Cell Myeloma	June 4, 2021	Phase 1\|Phase 2
NCT05055063	M.D. Anderson Cancer Center	Myeloma	May 18, 2022	Phase 1
NCT05060627	PETHEMA Foundation\|Adknoma Health Research	Relapsed Multiple Myeloma	December 20, 2021	Phase 1\|Phase 2
NCT05581875	Hellenic Society of Hematology\|GlaxoSmithKline	Multiple Myeloma\|Multiple Myeloma in Relapse\|Neoplasms\|Gammopathy, Monoclonal\|Paraproteinemias\|Blood Protein Disorders\|Haematologic Disease\|Corneal Disease\|Neoplasms, Plasma Cell	October 20, 2022	Phase 1\|Phase 2
NCT04822337	Wake Forest University Health Sciences\|Amgen\|GlaxoSmithKline	Multiple Myeloma	April 13, 2021	Phase 1\|Phase 2
NCT04398680	GlaxoSmithKline	Multiple Myeloma	April 20, 2021	Phase 1
NCT04177823	GlaxoSmithKline	Multiple Myeloma	December 9, 2019	Phase 1
NCT05393024	Fondazione EMN Italy Onlus	Multiple Myeloma	June 1, 2022
NCT05556798	Memorial Sloan Kettering Cancer Center	Multiple Myeloma	October 4, 2022	Phase 1
NCT03828292	GlaxoSmithKline	Multiple Myeloma	March 14, 2019	Phase 1
NCT05065047	M.D. Anderson Cancer Center	Multiple Myeloma	August 30, 2022	Phase 1
NCT04091126	GlaxoSmithKline	Multiple Myeloma	December 18, 2019	Phase 1
NCT04246047	GlaxoSmithKline	Multiple Myeloma	May 7, 2020	Phase 3
NCT05091372	M.D. Anderson Cancer Center	Myeloma Multiple	April 30, 2022	Phase 2
NCT05117008	Medical College of Wisconsin	Refractory Multiple Myeloma\|Relapse Multiple Myeloma	July 19, 2022	Phase 2
NCT04617925	European Myeloma Network\|GlaxoSmithKline	AL Amyloidosis	February 26, 2021	Phase 2
NCT05297240	PETHEMA Foundation\|GlaxoSmithKline	RELAPSED AND+OR REFRACTORY MULTIPLE MYELOMA	March 24, 2022
NCT05002816	Yale University\|GlaxoSmithKline	Multiple Myeloma	February 21, 2022	Phase 1\|Phase 2
NCT03525678	GlaxoSmithKline	Multiple Myeloma	June 18, 2018	Phase 2
NCT04680468	Abramson Cancer Center of the University of Pennsylvania\|GlaxoSmithKline	Myeloma	May 25, 2021	Phase 2
NCT04643002	Sanofi	Plasma Cell Myeloma Refractory	January 25, 2021	Phase 1\|Phase 2
NCT04896658	University of Maryland, Baltimore	Relapsed+Refractory Multiple Myeloma	January 1, 2022	Phase 1\|Phase 2
NCT02343042	Karyopharm Therapeutics Inc	Multiple Myeloma	October 2015	Phase 1\|Phase 2
NCT03763370	GlaxoSmithKline	Multiple Myeloma
NCT04549363	GlaxoSmithKline	Multiple Myeloma	May 13, 2021	Phase 3
NCT04808037	Hellenic Society of Hematology\|GlaxoSmithKline	Multiple Myeloma	February 22, 2021	Phase 1\|Phase 2
NCT04676360	Jacob Soumerai, MD\|GlaxoSmithKline\|Massachusetts General Hospital	Relapsed Plasmablastic Lymphoma\|Refractory Plasmablastic Lymphoma\|Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma	July 1, 2021	Phase 2
NCT05280275	Hellenic Society of Hematology\|GlaxoSmithKline	Multiple Myeloma\|Neoplasms\|Neoplasms, Plasma Cell\|Gammopathy, Monoclonal\|Paraproteinemias\|Blood Protein Disorders\|Haematologic Disease\|Corneal Disease	March 15, 2022	Phase 1\|Phase 2
NCT03732703	Multiple Myeloma Research Consortium\|AbbVie\|Celgene Corporation\|Eli Lilly and Company\|Genentech, Inc.\|Janssen, LP\|Takeda\|GlaxoSmithKline\|Karyopharm Therapeutics Inc	Relapsed Refractory Multiple Myeloma	April 1, 2019	Phase 1\|Phase 2
NCT05145816	University of Texas Southwestern Medical Center\|GlaxoSmithKline	AL Amyloidosis\|Amyloidosis	December 1, 2022	Phase 1\|Phase 2
NCT04126200	GlaxoSmithKline	Multiple Myeloma	October 7, 2019	Phase 1\|Phase 2
NCT04484623	GlaxoSmithKline	Multiple Myeloma	October 1, 2020	Phase 3
NCT03848845	GlaxoSmithKline\|Merck Sharp & Dohme LLC	Multiple Myeloma	March 14, 2019	Phase 1\|Phase 2
NCT05573802	Hellenic Society of Hematology\|GlaxoSmithKline	Multiple Myeloma\|Neoplasms\|Neoplasm, Plasma Cell\|Gammopathy, Monoclonal\|Paraproteinemias\|Blood Protein Disorders\|Haematologic Disease\|Corneal Disease	October 24, 2022	Phase 1\|Phase 2
NCT04162210	GlaxoSmithKline	Multiple Myeloma	April 2, 2020	Phase 3
NCT05493618	Hackensack Meridian Health\|Merck Sharp & Dohme LLC	Multiple Myeloma, Refractory	December 2022	Phase 1\|Phase 2
NCT05064358	GlaxoSmithKline	Multiple Myeloma	March 3, 2022	Phase 2
NCT04802356	PETHEMA Foundation\|GlaxoSmithKline	Multiple Myeloma	April 7, 2021	Phase 2
NCT04398745	GlaxoSmithKline	Multiple Myeloma	October 9, 2020	Phase 1

Appearance

Liquid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Ivo Demel, et al. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021. Br J Haematol. 2021 May;193(4):705-722.